Börse:
7,425€
-3,26%
Echtzeit-Aktienkurs Intra-Cellular Therapies
Bid:
7,400€
Ask:
7,450€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 407,60 Mio. EUR (54,90 Mio. x 7,425€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 3.521,25 | 971,15 | 1.647,93 | - |
| KGV | - | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Intra-Cellular Therapies Aktie
Börsenkurse Intra-Cellular Therapies
| Euro Indikation | 7,400€ | 0 | 7,450€ | 0 | 7,425€ | -3,26% |
| Lang & Schwarz | 7,400€ | 1570 | 7,450€ | 1570 | 7,425€ | -2,62% |
| Dollar Indikation | 8,150$ | 0 | 8,318$ | 0 | 8,234$ | -3,13% |
| Börse Stuttgart | 7,300€ | 0 | 7,450€ | 0 | 7,375€ | -1,01% |
| Tradegate | 7,400€ | 406 | 7,450€ | 403 | 7,425€ | -3,26% |
Fundamentaldaten der Intra-Cellular Therapies Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 0,00 Mio. | -155,13 Mio. | -155,13 Mio. | -2,84 | 0,00% | - | - |
| 2017 | 0,25 Mio. | -98,83 Mio. | -97,77 Mio. | -2,12 | 0,00% | - | 1647,93 |
| 2016 | 0,33 Mio. | -115,36 Mio. | -116,43 Mio. | -2,69 | 0,00% | - | 971,15 |
| 2015 | 0,09 Mio. | -104,79 Mio. | -104,79 Mio. | -2,91 | 0,00% | - | 3521,25 |
| 2014 | 0,58 Mio. | -30,69 Mio. | -30,69 Mio. | -1,07 | 0,00% | - | 379,60 |
| 2013 | 2,74 Mio. | -26,85 Mio. | -26,87 Mio. | -1,56 | 0,00% | - | 60,11 |
| 2012 | 3,12 Mio. | -16,56 Mio. | -16,59 Mio. | -1,63 | 0,00% | - | 34,77 |
| 2011 | 22,33 Mio. | 11,16 Mio. | 11,09 Mio. | 0,71 | 0,00% | 10,46 | 3,73 |
Profil der Intra-Cellular Therapies Aktie
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. Intra-Cellular Therapies was founded by Paul Greengard on August 29, 2013 and is headquartered in New York, NY.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen